Skip to main content

Piloting Melanoma Research and Local Cancer Care: An Oncology Data Advisor® Editorial Board Spotlight Interview With Richard Carvajal, MD

Oncology Data Advisor® · Piloting Melanoma Research and Local Cancer Care With Richard Carvajal, MD This interview is the first in a new series spotlighting the Oncology Data Advisor® Editorial Board, featuring Dr. Richard Carvajal, Director of Medical Oncology at Northwell Health Cancer Institute. Dr. Carvajal tells the story of how he became a melanoma researcher and shares his passions for developing targeted therapies for unique clinical subsets of melanoma and for providing high-...

Continue reading

Melphalan for Liver-Directed Treatment of Uveal Melanoma With Richard Carvajal, MD

Recently, the FDA approved melphalan for liver-directed treatment of uveal melanoma. In this interview, Oncology Data Advisor Editorial Board member Dr. Richard Carvajal, Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute in New York, discusses the approval and the trial that led to it, as well as share exciting insights on the potential future landscape of this rare disease.   Oncology Data Advisor: Welcome to Oncology Data Advisor, a digital re...

Continue reading

Piloting Melanoma Research and Local Cancer Care: An Oncology Data Advisor® Editorial Board Spotlight Interview With Richard Carvajal, MD

This interview is the first in a new series spotlighting the Oncology Data Advisor® Editorial Board, featuring Dr. Richard Carvajal, Director of Medical Oncology at Northwell Health Cancer Institute. Dr. Carvajal tells the story of how he became a melanoma researcher and shares his passions for developing targeted therapies for unique clinical subsets of melanoma and for providing high-quality cancer care for patients in their own neighborhoods.  

Continue reading

The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD

Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this rare ocular malignancy. In this interview, Dr. Richard Carvajal, Associate Professor of Medicine at Columbia University Irving Medical Center and editorial board member of Oncology Data Advisor, discusses the practice-changing significance of the approval of tebentafusp and delves further into future directions in the development of treatments for uveal melanoma.  

Continue reading

The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD

Oncology Data Advisor™ · The Groundbreaking Approval of Tebentafusp for Uveal Melanoma With Richard Carvajal, MD Recently, the FDA granted approval to tebentafusp for the treatment of patients with human leukocyte antigen (HLA)-A*02:01–positive unresectable or metastatic uveal melanoma, marking the first agent to be approved for this rare ocular malignancy. In this interview, Dr. Richard Carvajal, Associate Professor of Medicine at Columbia University Irving Medical Center and edito...

Continue reading